Search

ADMA Biologics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

9.47 0.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.23

Max

9.52

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.5M

38M

Pardavimai

9.9M

124M

P/E

Sektoriaus vid.

13.929

57.002

Pelnas, tenkantis vienai akcijai

0.16

Pelno marža

30.405

Darbuotojai

640

EBITDA

-3.8M

57M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+80.66% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

158M

2.2B

Ankstesnė atidarymo kaina

8.83

Ankstesnė uždarymo kaina

9.47

Naujienos nuotaikos

By Acuity

100%

0%

325 / 340 reitingas Healthcare

ADMA Biologics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 20:02; UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

2026-08-12 19:46; UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

2026-08-11 22:56; UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

2026-08-07 19:46; UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

2026-08-06 20:02; UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

2026-08-05 23:02; UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

2026-08-04 19:46; UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

2026-08-03 19:16; UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

2026-07-31 20:06; UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

2026-07-30 19:39; UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

2026-07-29 18:17; UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

2026-07-28 20:06; UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

2026-07-27 19:41; UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

2026-07-24 19:26; UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

2026-07-22 18:36; UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

2026-07-21 19:36; UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

2026-07-20 19:46; UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Akcijų palyginimas

Kainos pokytis

ADMA Biologics Inc Prognozė

Kainos tikslas

By TipRanks

80.66% į viršų

12 mėnesių prognozė

Vidutinis 17 USD  80.66%

Aukščiausias 21 USD

Žemiausias 12 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ADMA Biologics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

325 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat